Committe :

Organizing Committee :

Takao Hayakawa ¹⁾, Kindai Univ., Japan

Takashi Aoi, Kobe Univ., Japan

Akifumi Matsuyama, NIBIO, Japan

Akihiro Umezawa, NICHD, Japan

  John Petricciani, IABS President, USA

Yoji Sato, National Institute of Health Sciences, Japan

Yuzo Toda, FIRM Chairperson, Japan

Masayuki Yamato, Tokyo Women’s Medical Univ., Japan

  Daisaku Sato, PMDA, Japan

Program Committee :

Takao Hayakawa ¹⁾, Kindai Univ., Japan

Takashi Aoi, Kobe Univ., Japan

Mira Choi, MFDS, Korea

Joyce Frey-Vasconcells, formerly with FDA, USA

Karin Hoogendoorn, Novartis, Switzerland

Surapol Issaragrisil, Mahidol Univ., Thailand

Akifumi Matsuyama, NIBIO, Japan

Jimmy McBlane, MHRA, UK

John Petricciani, IABS President, formerly with WHO & FDA, USA

Matthias Renner, PEI, Germany

Anthony Ridgway, Health Canada, Canada

Yoji Sato, National Institute of Health Sciences, Japan

Glenn Smith, TGA, Australia

Glyn Stacey, UKSCB/NIBSC, UK

Yuzo Toda, FIRM Chairperson, Japan

Jean-Hugues Trouvin, Univ. Paris Descartes, France

Masayuki Yamato, Tokyo Women’s Medical Univ., Japan

Daisaku Sato, PMDA, Japan

Masayuki Shibasaki, FIRM Secretariat, Japan

Akihiro Umezawa, NICHD, Japan

Ivana Knezevic,WHO

Pierrette Zorzi-Morre, Formerly with AFSSAPs, France

  ¹⁾Chair of Cell & Gene Therapy Committee, IABS

Meeting Management :

IABS, Geneva, Switzerland